Vimarsana
Biggest News Aggregation in the World

Hertzel Gerstein News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Hertzel Gerstein. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Hertzel Gerstein Today - Breaking & Trending Today

Ozempic Cuts Risk of Kidney Disease Death in People with Diabetes - Vimarsana News

Ozempic Cuts Risk of Kidney Disease Death in People with Diabetes

Semaglutide, the same compound in obesity drug Wegovy, slashes risk of kidney failure and death for people with type 2 diabetes

COVID could increase risk of developing diabetes by up to 22%, Canadian study shows - National - Vimarsana News

COVID could increase risk of developing diabetes by up to 22%, Canadian study shows - National

A University of British Columbia study looking at more than 600,000 people found a higher rate of diabetes in those who’d been infected with COVID-19.

COVID could increase risk of developing diabetes by up to 22%, Canadian study shows - Vimarsana News

COVID could increase risk of developing diabetes by up to 22%, Canadian study shows

A University of British Columbia study looking at more than 600,000 people found a higher rate of diabetes in those who’d been infected with COVID-19.

Source: q107.com
People who suffer from diabetes AND a cognitive impairment are at increased risk of heart disease - Vimarsana News

People who suffer from diabetes AND a cognitive impairment are at increased risk of heart disease

Researchers led by Tel Aviv University, Israel, said the risk could be higher because patients were forgetting to take their medication. But the study was observational.

ADA 2021: Hanmi's GLP-1 drug, returned by Sanofi, curbs cardiovascular, kidney issues while tackling Type 2 diabetes - Vimarsana News

ADA 2021: Hanmi's GLP-1 drug, returned by Sanofi, curbs cardiovascular, kidney issues while tackling Type 2 diabetes

Jun 28, 2021 5:19pm Hanmi Pharmaceutical's treatment, once partnered with Sanofi, reduced the risk of nonfatal heart attack, nonfatal stroke or death from cardiovascular or undetermined causes by 27% compared to placebo. (Getty Images) Hanmi Pharmaceutical may no longer have a diabetes partner in Sanofi, but newly released results for its GLP-1 drug could move the needle for Type 2 diabetes patients with a history of cardiovascular disease, kidney disease or both. Efpeglenatide reduced the risk of heart attack, stroke and death and also slowed the decline in patients’ kidney fun...